Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Neuroleptic malignant syndrome after risperidone therapy in a critically ill patient with mixed connective tissue disease-associated interstitial lung disease:A case report.

Created on 12 Nov 2026

Authors

Shotaro Otani, Saki Saijo, Hitoshi Chikami, Kota Miyoshi, Konomi Moriwaki, Masaki Terazawa, Hiroki Sato, Yusuke Akimoto, Toshiyuki Nunomura, Manabu Ishihara, Taiga Itagaki, Jun Oto

Published in

The journal of medical investigation : JMI. Volume 73. Issue 3.4. Pages 558-560.

Abstract

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening adverse reaction to dopamine-blocking agents. Although atypical antipsychotics are generally considered to carry a lower risk than typical agents, NMS may occur even at therapeutic doses, particularly in critically ill patients. Critically ill individuals with systemic inflammatory diseases may present with diagnostic challenges because the clinical features of NMS overlap with those of infection or disease exacerbation.
A 47-year-old woman with mixed connective tissue disease-associated interstitial lung disease (MCTD-ILD) developed acute respiratory failure requiring mechanical ventilation and high-dose corticosteroid therapy. During sedation weaning, risperidone was initiated at 3 mg/day to manage agitation. Within 48 hours, she developed a high-grade fever, tachypnea, and a marked creatine kinase elevation without muscle rigidity, fulfilling the diagnostic criteria for NMS. Discontinuation of risperidone and a single administration of dantrolene led to a clinical improvement. However, recurrent NMS occurred after initial stabilization, necessitating reintubation and the reinstitution of dantrolene. The patient ultimately recovered and was discharged without recurrence.
NMS can occur and recur after therapeutic-dose atypical antipsychotic use in critically ill patients with systemic inflammatory conditions. Early recognition and close biochemical monitoring are essential when prescribing dopamine antagonists in the ICU setting. J. Med. Invest. 73 : 558-560, August, 2026.

PMID:
43014794
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement